MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526390 | Name: Carmoterol HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carmoterol, also known as CHF-4226 and TA-2005, is a long-acting, and selective beta 2-adrenoceptor agonist. TA-2005 exerts potent bronchodilating effects with a long duration of action in vivo, and its potency ratios to the other reference drugs were greater in antigen- than spasmogen-induced bronchoconstriction models.

Chemical Structure

Carmoterol HCl
Carmoterol HCl
CAS#137888-11-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 526390

Name: Carmoterol HCl

CAS#: 137888-11-0 (HCl)

Chemical Formula: C21H25ClN2O4

Exact Mass:

Molecular Weight: 404.89

Elemental Analysis: C, 62.30; H, 6.22; Cl, 8.76; N, 6.92; O, 15.81

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
147568-66-9 (free base) 137888-11-0 (HCl)
Synonym
TA-2005; TA 2005; TA2005. CHF 4226.01; CHF-4226.; CHF4226.; TA-2005 hydrochloride; Carmoterol HCl; Carmoterol hydrochloride
IUPAC/Chemical Name
2(1H)-Quinolinone, 8-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)-, (R-(R*,R*))-, hydrochloride
InChi Key
SYCWERNQGSKYAG-QVRIGTRMSA-N
InChi Code
InChI=1S/C21H24N2O4.ClH/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21;/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26);1H/t13-,19+;/m1./s1
SMILES Code
O=C1NC2=C(C([C@@H](O)CN[C@H](C)CC3=CC=C(OC)C=C3)=CC=C2O)C=C1.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 147568-66-9 (Carmoterol free base) 137888-11-0 (Carmoterol hydrochloride)

Preparing Stock Solutions

The following data is based on the product molecular weight 404.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rossoni G, Manfredi B, Razzetti R, Civelli M, Berti F. Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther. 2007;20(3):250-7. PubMed PMID: 16533614. 2: Matsukawa M, Takeda K, Shima H, Tagawa K, Banno K, Sato T. Enzyme-linked immunosorbent assay for TA-2005-glucuronide in human plasma. J Pharm Biomed Anal. 1998 Jun;17(2):245-54. PubMed PMID: 9638577. 3: Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol. 1998 Jan;53(1):128-34. PubMed PMID: 9443940. 4: Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting, and selective beta 2-adrenoceptor agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other beta 2-agonists. Biol Pharm Bull. 1994 Aug;17(8):1047-52. PubMed PMID: 7820105. 5: Voss HP, Donnell D, Bast A. Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol. 1992 Dec 1;227(4):403-9. PubMed PMID: 1359974. 6: Voss HP, Shukrula S, Wu TS, Donnell D, Bast A. A functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther. 1994 Oct;271(1):386-9. PubMed PMID: 7965739. 7: Kikkawa H, Naito K, Ikezawa K. Tracheal relaxing effects and beta 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn J Pharmacol. 1991 Oct;57(2):175-85. PubMed PMID: 1687479. 8: Kikkawa H, Kurose H, Isogaya M, Sato Y, Nagao T. Differential contribution of two serine residues of wild type and constitutively active beta2-adrenoceptors to the interaction with beta2-selective agonists. Br J Pharmacol. 1997 Jul;121(6):1059-64. PubMed PMID: 9249239; PubMed Central PMCID: PMC1564789. 9: Płusa T. [Novel controllers of airway obstruction in COPD patients]. Pol Merkur Lekarski. 2011 Jan;30(175):5-9. Polish. PubMed PMID: 21542237. 10: Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, Tate CG. The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor. Nature. 2011 Jan 13;469(7329):241-4. doi: 10.1038/nature09746. PubMed PMID: 21228877; PubMed Central PMCID: PMC3023143. 11: Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, Trevethick M. A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. J Pharmacol Toxicol Methods. 2008 Nov-Dec;58(3):189-97. doi: 10.1016/j.vascn.2008.06.003. PubMed PMID: 18652905. 12: Matera MG, Cazzola M. ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs. 2007;67(4):503-15. Review. PubMed PMID: 17352511. 13: Patel S, Summerhill S, Stanley M, Perros-Huguet C, Trevethick MA. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor. Pulm Pharmacol Ther. 2011 Apr;24(2):247-55. doi: 10.1016/j.pupt.2010.11.004. PubMed PMID: 21134482. 14: Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr Opin Pulm Med. 2010 Jan;16(1):6-12. doi: 10.1097/MCP.0b013e32833303d2. Review. PubMed PMID: 19816179. 15: Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015 May 28;58(10):4131-64. doi: 10.1021/jm5013227. PubMed PMID: 25587755. 16: Capacchi S, Lipreri M, Rizzi A, Caló C, Peveri T, Catinella S. 1H NMR discrimination of CHF4226.01 diastereoisomers in DMSO-d6. Magn Reson Chem. 2009 Jul;47(7):551-61. doi: 10.1002/mrc.2427. PubMed PMID: 19373771. 17: Spina D. Current and novel bronchodilators in respiratory disease. Curr Opin Pulm Med. 2014 Jan;20(1):73-86. doi: 10.1097/MCP.0000000000000012. Review. PubMed PMID: 24247039. 18: Katritch V, Reynolds KA, Cherezov V, Hanson MA, Roth CB, Yeager M, Abagyan R. Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J Mol Recognit. 2009 Jul-Aug;22(4):307-18. doi: 10.1002/jmr.949. PubMed PMID: 19353579; PubMed Central PMCID: PMC2693451. 19: Fuso L, Mores N, Valente S, Malerba M, Montuschi P. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477-95. Review. PubMed PMID: 23409722. 20: Ridolo E, Montagni M, Olivieri E, Riario-Sforza GG, Incorvaia C. Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:425-32. doi: 10.2147/COPD.S49179. Review. PubMed PMID: 24082783; PubMed Central PMCID: PMC3785397.